| 000 | 01880 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513135735.0 | ||
| 264 | 0 | _c19980407 | |
| 008 | 199804s 0 0 eng d | ||
| 022 | _a0556-6177 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHidalgo, O F | |
| 245 | 0 | 0 |
_aResults of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon. _h[electronic resource] |
| 260 |
_bRevista de medicina de la Universidad de Navarra _c |
||
| 300 |
_a6-12 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xsecondary |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFever _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypotension _xchemically induced |
| 650 | 0 | 4 |
_aImmunologic Factors _xadministration & dosage |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 |
_aInterleukin-2 _xadministration & dosage |
| 650 | 0 | 4 |
_aKidney Neoplasms _xpathology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xsecondary |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 |
_aSkin Neoplasms _xpathology |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aAramendÃa, J M | |
| 700 | 1 | _aAlonso, G | |
| 700 | 1 | _aFoncillas, J G | |
| 700 | 1 | _aBrugarolas, A | |
| 773 | 0 |
_tRevista de medicina de la Universidad de Navarra _gvol. 40 _gno. 3 _gp. 6-12 |
|
| 999 |
_c9467892 _d9467892 |
||